Dr. Reddy’s announces the Launch of Paricalcitol Capsules Business Wire HYDERABAD, India -- June 25, 2014 Dr. Reddy’s Laboratories (NYSE: RDY) announced today that it has launched Paricalcitol Capsules, 1 mcg, 2 mcg and 4 mcg, a therapeutic equivalent generic version of ZEMPLAR^® (Paricalcitol) Capsules in the US market on June 24, 2014, following the approval by the United States Food & Drug Administration (USFDA). The ZEMPLAR^® brand and generic had U.S. sales of approximately $109.6 Million MAT for the most recent twelve months ending in March 2014 according to IMS Health*. Dr. Reddy’s Paricalcitol Capsules 1 mcg, 2 mcg and 4 mcg are available in bottle counts of 30. Disclaimer This press release includes forward-looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future. About Dr. Reddy’s Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Major therapeutic focus is on gastro-intestinal, cardiovascular, diabetology, oncology, pain management and anti-infective. Major markets include India, USA, Russia-CIS and Europe apart from other select geographies within Emerging Markets. For more information, log on to: www.drreddys.com ZEMPLAR^® is a registered trademark of AbbVie INC. *IMS National Sales Perspectives: Retail and Non-Retail MAT March 2014 Contact: Dr. Reddy’s Media: SVS Chowdary at firstname.lastname@example.org / +91-40- 49002448 or Investors and Financial Analysts: Kedar Upadhye at email@example.com / +91-40-66834297 Saunak Savla at firstname.lastname@example.org / +91-40-49002135 Milan Kalawadia (USA) at email@example.com / +1-609-375-9831
Dr. Reddy’s announces the Launch of Paricalcitol Capsules
Press spacebar to pause and continue. Press esc to stop.